CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years
CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years
复制标题
DOI：
10.1086/533467
复制
发表时间：
2008-04-15
影响因子：
11.8
通讯作者：
Cameron, D. W.
中科院分区：
文献类型：
--
作者：
Cooper, C. L.;Angel, J. B.;Cameron, D. W.
背景。人类免疫缺陷病毒（HIV）感染的人对丙型肝炎病毒（HBV）疫苗接种反应不足。 CPG 7909是一种寡脱氧核苷酸，含有免疫抑制的CPG基序，可通过Toll-like受体激活人B和浆细胞样树突状细胞9。 48周。现在，我们报告疫苗接种后5年的数据。进行了一项随机，双盲对照试验，以确定接受有效抗逆转录病毒疗法的成人HIV感染受试者中HBV疫苗的临床安全性和免疫原性。 HBV敏感受试者（其中一半）以前经历了疫苗接种失败，在0、1和2个月接种疫苗，并使用双重成年剂量的重组HBV疫苗，有或没有1 mg CpG 7909（每ARM 19个受试者） 。以6个月的时间间隔测量了对HBV表面抗原（抗HB）抗体的滴度，长达60个月。在CpG 7909受体中，参与者达到和保留血清保护的比例（表面抗体滴度，> = 10 miU/ml）更大（在所有时间点，p <.05）。在CPG 7909组中，几何平均抗HBS滴度在所有测量的时间点上都高于对照组（没有CPG 7909辅助）。 CPG 7909的免疫刺激性能提出了在HIV感染患者和其他HBV疫苗 - 甲氧疾病种群中实现长期保护的重要策略。
Background. Human immunodeficiency virus (HIV)-infected persons are hyporesponsive to hepatitis B virus (HBV) vaccination. CPG 7909 is an oligodeoxynucleotide containing immunostimulatory CpG motifs that activate human B and plasmacytoid dendritic cells via Toll-like receptor 9. We previously reported that addition of CPG 7909 to a commercial HBV vaccine enhanced the kinetics, magnitude, and longevity of the seroprotective response over 48 weeks. We now report data for the 5-year period following vaccination.Methods. A randomized, double-blind, controlled trial was conducted to determine clinical safety and immunogenicity of HBV vaccine in adult HIV-infected subjects receiving effective antiretroviral therapy. HBV-susceptible subjects, one-half of whom had experienced previous vaccination failure, were vaccinated at 0, 1, and 2 months with a double adult dose of recombinant HBV vaccine, with or without 1 mg of CPG 7909 (19 subjects per arm). Titers of antibody to HBV surface antigen (anti-HBs) were measured at 6-month intervals for up to 60 months.Results. The proportion of participants achieving and retaining seroprotection (surface antibody titers, >= 10 mIU/mL) was greater in CPG 7909 recipients (P < .05 at all time points). Geometric mean anti-HBs titers were higher in the CPG 7909 group than in the control group (without CPG 7909 adjuvant) at all measured time points.Conclusions. The immunostimulatory properties of CPG 7909 present an important strategy in achieving long-term protection in HIV-infected patients and other HBV vaccine-hyporesponsive populations.